Clinical trials: Stroke, Acute
Acute Ischemic Stroke
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
The purpose of this trial is to determine if intravenous administration of the metal ion trapping agent DP-b99 up to 9 hours following acute ischemic stroke onset, and then for 3 additional days (4 consecutive days in total) is…
- Trial name
- MACSI (NCT00893867)
- Testing
- DP-b99
- Where
- 154 sites in United States, Austria and 16 more
- Volunteers
- 446 people
- Sponsor
- D-Pharm Ltd.
Acute Ischemic Stroke
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
- Trial name
- ACT-IVATE (NCT07742098)
- Testing
- NTS-521
- Volunteers
- 140 people
- Sponsor
- NeuroTrauma Sciences, LLC
Stroke
Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
The purpose of this study is: To assess the neurological outcome in acute ischemic stroke patients treated with NTx®-265, when compared with patients given a placebo control.
- Trial name
- REGENESIS-LED (NCT00938314)
- Testing
- human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- Stem Cell Therapeutics Corp.
Pharmacodynamics, Pharmacokinetics
Study of BB-025, Alone and After BB-031, in Healthy Volunteers
The goal of this 2-part clinical trial is to learn about the safety and pharmacokinetics (PK) of a single dose of BB-025 when given on its own and after being given BB-031.
- Conditions
- Pharmacodynamics, Pharmacokinetics, Healthy Volunteers
- Trial name
- NCT07202663
- Testing
- BB-025, BB-031
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Basking Biosciences, Inc.
Stroke, Acute
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
The primary purpose of this study is to determine if a single dose of nerinetide can reduce global disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen…
- Trial name
- ESCAPE-NEXT (NCT04462536)
- Testing
- Nerinetide
- Where
- 81 sites in United States, Australia and 7 more
- Volunteers
- 850 people
- Sponsor
- NoNO Inc.
Stroke, Acute
Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke
This study will assess the potential efficacy and safety of TSC as early treatment for both ischemic and hemorrhagic stroke when administered while subject is in ambulance being transported to hospital.
- Trial name
- PHAST-TSC (NCT03763929)
- Testing
- Trans-Sodium Crocetinate
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Ischemic Stroke Hospitalized, Impairment, Cognitive
A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment
The goal of this clinical trial is to learn if Extract of Ginkgo Biloba Leaves Tablets help improve thinking and memory in people aged 55 years and older who had an ischemic stroke (a type of stroke caused by a blocked blood…
- Trial name
- GiCIIS (NCT07220538)
- Testing
- Extract of Ginkgo Biloba Leaves Tablets 240 mg (2 x 40 mg, t.i.d.), Standard of care (SoC) Group
- Where
- 34 sites in China
- Volunteers
- 400 people
- Sponsor
- Dr. Willmar Schwabe GmbH & Co. KG
Stroke, Stroke, Acute
Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology
The purpose of this study is to assess the ability of the Fluids Monitor to detect hemispheric bioimpedance asymmetry associated with acute brain pathology in patients presenting with suspected Acute Ischemic Stroke (AIS).
- Conditions
- Stroke, Stroke, Acute, Ischemic Stroke, Hemorrhage
- Trial name
- VITAL (NCT03148340)
- Testing
- VIPS Monitoring
- Where
- 5 sites in United States
- Volunteers
- 287 people
- Sponsor
- Cerebrotech Medical Systems, Inc.
Acute Ischemic Stroke
A Randomized Placebo-controlled Multicenter Trial to Evaluate the Efficacy and Safety of JTR-161, Allogeneic Human Dental Pulp Stem Cell, in Patients With Acute Ischemic stRoke (J-REPAIR)
The objective of this study is to evaluate the safety and efficacy of a single intravenous administration of JTR-161 (allogeneic stem cell product derived from the dental pulp of healthy adult humans) to patients with acute…
- Trial name
- J-REPAIR (NCT04608838)
- Testing
- JTR-161
- Where
- Japan
- Volunteers
- 79 people
- Sponsor
- Teijin Pharma Limited
Stroke, Acute, Venous Thromboembolism
GEKO Venous Thromboembolism Prevention Study
This multicentre, randomised geko™ venous thromboembolism (VTE) prevention study will prospectively collect clinical data on VTE occurrences in immobile patients after stroke, who will be randomised, on a 1:1 allocation, to…
- Conditions
- Stroke, Acute, Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism
- Trial name
- NCT05476913
- Testing
- geko™ device
- Where
- 18 sites in United Kingdom
- Volunteers
- 1,200 people
- Sponsor
- Firstkind Ltd
Acute Ischemic Stroke
Safety and Efficacy of J147 in Acute Ischemic Stroke
The goal of this clinical trial is to find out if the drug J147 improves outcomes for persons who have had an ischemic stroke. It also will learn about the safety of J147 when given by injection to stroke patients.
- Trial name
- JUMPSTART (NCT07430917)
- Testing
- J147 Emulsion for Injection
- Where
- 5 sites in United States
- Volunteers
- 196 people
- Sponsor
- Abrexa Pharmaceuticals, Inc.
Acute Ischemic Stroke
Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.
The purpose of this study is to determine the efficacy and safety of QHRD106 injection in treating acute ischemic stroke.
- Trial name
- NCT07396337
- Testing
- QHRD106 Injection (Low-dose group), QHRD106 Injection (Middle-dose group), QHRD106 Injection (High-dose group)
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
Acute Ischemic Stroke AIS, Cerebral Arterial Disease
Pulse Endovascular ReperFUSION for Acute Ischemic Stroke
Prospective, multi-center, single-arm early feasibility study enrolling a minimum of 15 subjects at up to a minimum of 3 active investigational sites in the United States.
- Trial name
- PERFUSION AIS (NCT06052969)
- Testing
- Pulse NanoMED System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Euphrates Vascular, Inc.
Acute Ischemic Stroke
Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial of the Combined Lysis of Thrombus With Ultrasound and Systemic Tissue Plasminogen Activator (tPA) for Emergent Revascularization in Acute Ischemic Stroke
This is a randomized, placebo-controlled, phase 3 clinical trial to evaluate the efficacy and safety of transcranial ultrasound (US) as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute…
- Trial name
- CLOTBUST-ER (NCT01098981)
- Testing
- Transcranial ultrasound as an adjunctive therapy to tPA, Standard of care tPA therapy for acute ischemic stroke
- Where
- United States
- Volunteers
- 675 people
- Sponsor
- Cerevast Therapeutics, Inc.
Stroke, Ischemic
COMPLETE: International Acute Ischemic Stroke Registry With the Penumbra System Aspiration Including the 3D Revascularization Device
The purpose of this registry is to collect performance and safety data on the Penumbra System including the 3D Revascularization Device in a real world patient population with acute ischemic stroke (AIS) secondary to intracranial…
- Trial name
- NCT03464565
- Testing
- Penumbra System
- Where
- 42 sites in United States, France and 4 more
- Volunteers
- 650 people
- Sponsor
- Penumbra Inc.
Ischemic Stroke
Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care
This clinical study is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (otaplimastat) and thrombolytic standard of care in acute ischemic stroke patient.
- Trial name
- SP-8203-3001 (NCT06660719)
- Testing
- SP-8203
- Where
- 2 sites in South Korea
- Volunteers
- 852 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.